Biology

A doctor sits down with a patient showing early signs of memory loss. The MRI is on file. The genetic test was done last month. But the spinal tap results haven’t come back yet, and the cognitive assessment from the referring clinic uses a different scoring system than what this hospital prefers. The doctor has to make a call with what’s available.

That’s not a hypothetical scenario. It’s the daily reality of Alzheimer’s diagnosis worldwide. And it’s the problem a team at Lausanne University Hospital set out to solve.

Place a single cell on a circular micropattern, a dinner-plate-sized arena at the cellular scale, and something strange happens. The cell doesn’t wander randomly. It starts tracing a petal-shaped loop, over and over, circling clockwise or counterclockwise with the determination of a figure skater. About half go clockwise, half counterclockwise. Until they don’t.

In 2023, the world spent over $200 billion on antibody drugs — treatments like Keytruda for cancer and Humira for autoimmune disease. But finding a single antibody that binds well enough to become a drug is like searching for a specific grain of sand on a beach. A typical drug discovery campaign screens thousands of candidates, each one requiring expensive lab tests to measure how tightly it grabs its target. Most fail.

Every year, millions of cancer patients lie inside the narrow tube of an MRI machine while a nurse injects gadolinium into their veins. The contrast agent makes tumors glow on the scan, which helps surgeons find them and track whether treatment is working. But gadolinium has a problem: it accumulates in the body. The brain, the bones, the kidneys. The metal stays there, sometimes permanently. Some patients have developed nephrogenic systemic fibrosis, a condition where connective tissue grows uncontrollably. A safer alternative has been the goal of contrast-agent research for a decade.

Here is where it gets interesting. A team of researchers at Islamic Azad University in Tehran has compiled the evidence for a material that might replace gadolinium entirely, and it does more than just light up tumors on a scan. A single injection of this stuff could make your cancer visible on MRI, deliver therapy directly to the tumor, and train your immune system to attack it, all at the same time.

In June 2026, a 62-year-old melanoma patient who had already failed two lines of therapy received an experimental vaccine. It wasn’t an off-the-shelf drug. It was built from the DNA of their own tumor, encoding 34 custom neoantigens selected by an algorithm trained on thousands of other patients’ cancers. Six months later, scans showed no new lesions.

That vaccine, Moderna’s mRNA-4157 (now called V940), is the most visible example of a quiet revolution in the open-source code repositories where computational biologists build the tools that make personalized cancer immunotherapy possible. One of those tools, pVACtools, just got its biggest update yet.

Every year, millions of parents-to-be stare at ultrasound images, hoping for reassurance and bracing for uncertainty. For about 6% of all pregnancies worldwide, the scan reveals something unexpected: a structural anomaly in the developing fetus. A heart that formed differently. A spine that didn’t close. In the moments that follow, a grueling diagnostic odyssey begins — one that, even with the best genetic sequencing technology, can take months or years and often ends without answers. A new artificial intelligence system from Zhejiang University, described in a preprint posted this week, just made that journey dramatically shorter. Its name is DeepBD, and it might be the closest thing yet to a diagnostic safety net for the most vulnerable patients who will never speak for themselves.

Imagine holding a map of every street, alley, and footpath in New York City — all 100,000-plus connections, down to the smallest synapse. Now imagine running traffic through that map to see where the jams form, where cars flow freely, and which intersections secretly control the whole system. That, in essence, is what neuroscientist Stavros Therianos has just done with a brain.

Every minute, millions of your cells face a decision. A stem cell in your bone marrow must choose: become a red blood cell or a white one? An immune cell must decide: multiply to fight an infection, or quietly self-destruct? A cell in a developing embryo must pick its destiny: skin, nerve, or muscle?

For decades, biologists have modelled these life-or-identity decisions using a beautifully simple idea called the genetic toggle switch — two genes that mutually inhibit each other, locking a cell into one stable state or another. It is one of the most famous concepts in molecular biology, taught in textbooks and used to understand everything from embryonic development to cancer. But a new mathematical analysis from the University of Edinburgh, published this week, reveals a blind spot in this iconic model that may have been quietly misleading researchers for years. The problem? The way we’ve been modelling cell division.